Jochen Zisowsky
Overview
Explore the profile of Jochen Zisowsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keunecke A, Hoefman S, Drenth H, Zisowsky J, Cleton A, Ploeger B
Br J Clin Pharmacol
. 2020 May;
86(12):2362-2376.
PMID: 32358822
Aim: Regorafenib is an oral multikinase inhibitor with clinical efficacy in a range of advanced solid tumours. A population pharmacokinetic (PK) model was developed to evaluate the variability of the...
2.
Krause A, Zisowsky J, Dingemanse J
Pulm Pharmacol Ther
. 2018 Mar;
49:140-146.
PMID: 29501590
Background: Macitentan is the first endothelin receptor antagonist with demonstrated efficacy on morbidity and mortality in pulmonary arterial hypertension (PAH) in the pivotal study SERAPHIN. Methods: The pharmacokinetics (PK) of...
3.
Zisowsky J, Gehin M, Kusic-Pajic A, Krause A, Beghetti M, Dingemanse J
Paediatr Drugs
. 2017 Jan;
19(2):121-130.
PMID: 28078552
Background: Bosentan is approved for use in adult patients with pulmonary arterial hypertension. The primary aim of the pharmacokinetic modeling was the provision of a systematic guidance for study design...
4.
Zisowsky J, Krause A, Dingemanse J
Pharmaceutics
. 2016 Oct;
2(4):364-388.
PMID: 27721363
Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in...
5.
Krause A, Zisowsky J, Strasser D, Gehin M, Sidharta P, Groenen P, et al.
Clin Pharmacokinet
. 2015 Dec;
55(7):813-821.
PMID: 26692193
Background And Objective: The chemoattractant receptor-homologous molecule expressed on T helper-2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D2 (PGD2), a key mediator in inflammatory disorders. Two selective and...
6.
Gehin M, Strasser D, Zisowsky J, Farine H, Groenen P, Dingemanse J, et al.
J Clin Pharmacol
. 2015 Feb;
55(7):787-97.
PMID: 25655470
The chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D2 , a key mediator in inflammatory disorders. In this randomized, double-blind, placebo-controlled study...
7.
Zisowsky J, Fuseau E, Bruderer S, Krause A, Dingemanse J
Eur J Clin Pharmacol
. 2014 Jan;
70(4):409-19.
PMID: 24458541
Purpose: This paper describes the pharmacokinetic/pharmacodynamic modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage (aSAH), and the impact of collecting data in an intensive care unit (ICU) setting. Factors...
8.
Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J
Pharmacology
. 2012 Feb;
89(1-2):53-7.
PMID: 22302127
Background/aims: The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous formulation of almorexant in healthy subjects. Methods: A pilot phase...
9.
Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack M, Osmak M, et al.
Biochem Pharmacol
. 2006 Nov;
73(2):298-307.
PMID: 17097621
Platinum sensitivity and platinum resistance may involve altered activity of transport proteins. In order to assess the role of drug uptake and efflux in this phenomenon, we compared the expression...
10.
Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota H, et al.
Am J Pathol
. 2005 Nov;
167(6):1477-84.
PMID: 16314463
Cis-platin is an effective anti-neoplastic agent, but it is also highly nephrotoxic. Here, we clearly identify the human organic cation transporter 2 (hOCT2) as the critical transporter for cis-platin nephrotoxicity...